Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: Effects of gender, age, and region

Current Medical Research and Opinion

Volumn 30, Issue 9, 2014, Pages 1875-1881

  Rapoport, Bernardo L ^a  

^a Medical Oncology Centre of Rosebank   (South Africa)

Author keywords

Chemotherapy; Nausea and vomiting; Prevention; Supportive care

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; DEXAMETHASONE; MORPHOLINE DERIVATIVE; ONDANSETRON;

ADOLESCENT; ADULT; AGE; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; ONDANSETRON; PROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84906826692     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.925866     Document Type: Article

References (23)

1. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219-27
2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-V.2.2010: Antiemesis. Available at: https://www.nccn.org/store/login/ login.aspx?ReturnURL=http://www.nccn.org/professionals/physician-gls/pdf/ antiemesis.pdf. Last accessed 2 June 2014
3. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-36
4. Neymark N, Crott R. Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: retrospective analysis of three clinical trials. Support Care Cancer 2005;13:812-18
5. Annemans L, Strens D, Lox E, et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 2008;16:905-15
6. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005;13:117-21
7. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12:1143-50
8. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-19
9. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
10. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23: 2822-30
11. Emend (aprepitant) [package insert]. Whitehouse Station, NJ: Merck & Co. Inc., 2003
12. Grunberg S, Chua D, Maru S, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011;29:1495-501
13. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47
14. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010;18:423-31
15. Boice J, Brown C, Taylor HJ, et al. Aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapies in patients with gastrointestinal cancer [ESMO GI annual meeting abstract]. Ann Oncol 2009;20(Suppl 2):vii69
16. Rapoport B, Boice JA, Brown C, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer [EMSO-ECCO meeting abstract P-9048]. Eur J Cancer 2009;7(Suppl 7):519
17. Webb T, Hardwick J, Carides A, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic (MEC) chemotherapy in patients with breast cancer [SABCS annual meeting abstract]. Cancer Res 2010;69:1116
18. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26
19. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14:354-60
20. Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park) 2004;18:9-14
21. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J 2006;12:341-7
22. Hammer C, Fasching PA, Loehberg CR, et al. Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics 2010;11:943-50
23. Gralla RJ, Rapoport B, Hirdab J, et al. Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1,872 patients ( pts) in prospective randomized clinical phase III trials (RCTs) [ASCO annual meeting abstract 9057]. J Clin Oncol 2010;20(Suppl 15s):9057